Display options
Cite
Virgone C, Roganovic J, Vorwerk P, et al. Adrenocortical tumours in children and adolescents: The EXPeRT/PARTNER diagnostic and therapeutic recommendations. Pediatr Blood Cancer. 2021;68:e29025doi: 10.1002/pbc.29025.
Virgone, C., Roganovic, J., Vorwerk, P., Redlich, A., Schneider, D. T., Janic, D., Bien, E., López-Almaraz, R., Godzinski, J., Osterlundh, G., Stachowicz-Stencel, T., Brugières, L., Brecht, I. B., Thomas-Teinturier, C., Fresneau, B., Surun, A., Ferrari, A., Bisogno, G., & Orbach, D. (2021). Adrenocortical tumours in children and adolescents: The EXPeRT/PARTNER diagnostic and therapeutic recommendations. Pediatric blood & cancer, 68e29025. https://doi.org/10.1002/pbc.29025
Virgone, Calogero, et al. "Adrenocortical tumours in children and adolescents: The EXPeRT/PARTNER diagnostic and therapeutic recommendations." Pediatric blood & cancer vol. 68 (2021): e29025. doi: https://doi.org/10.1002/pbc.29025
Virgone C, Roganovic J, Vorwerk P, Redlich A, Schneider DT, Janic D, Bien E, López-Almaraz R, Godzinski J, Osterlundh G, Stachowicz-Stencel T, Brugières L, Brecht IB, Thomas-Teinturier C, Fresneau B, Surun A, Ferrari A, Bisogno G, Orbach D. Adrenocortical tumours in children and adolescents: The EXPeRT/PARTNER diagnostic and therapeutic recommendations. Pediatr Blood Cancer. 2021 Jun;68:e29025. doi: 10.1002/pbc.29025. PMID: 34174161.
Copy Download .nbib Format: NLM
Share it on

Pediatr Blood Cancer. 2021 Jun;68:e29025. doi: 10.1002/pbc.29025.

Adrenocortical tumours in children and adolescents: The EXPeRT/PARTNER diagnostic and therapeutic recommendations.

Pediatric blood & cancer

Calogero Virgone, Jelena Roganovic, Peter Vorwerk, Antje Redlich, Dominik T Schneider, Dragana Janic, Ewa Bien, Ricardo López-Almaraz, Jan Godzinski, Gustaf Osterlundh, Teresa Stachowicz-Stencel, Laurence Brugières, Ines B Brecht, Cécile Thomas-Teinturier, Brice Fresneau, Aurore Surun, Andrea Ferrari, Gianni Bisogno, Daniel Orbach

Affiliations

  1. Pediatric Surgery, Department of Women's and Children's Health, University Hospital of Padua, Padua, Italy.
  2. Department of Pediatrics, Clinical Hospital Center Rijeka, University of Rijeka, Rijeka, Croatia.
  3. Pediatric Oncology Department, Otto von Guericke University Children´s Hospital, Magdeburg, Germany.
  4. Clinic of Pediatrics, Dortmund Municipal Hospital, Dortmund, Germany.
  5. Department of Hematology and Oncology, University Children's Hospital, University of Belgrade, Belgrade, Serbia.
  6. Department of Pediatrics, Hematology and Oncology, Medical University, Gdansk, Poland.
  7. Pediatric Hematology and Oncology Unit, Hospital Universitario de Cruces, Barakaldo-Bizkaia, Spain.
  8. Department of Pediatric Surgery, Marciniak Hospital, Wroclaw, Poland.
  9. Department of Pediatric Traumatology and Emergency Medicine, Medical University, Wroclaw, Poland.
  10. Department of Pediatrics, The Queen Silvia Children's Hospital, University of Gothenburg, Gothenburg, Sweden.
  11. Gustave Roussy Cancer Center, Department of Children and Adolescents Oncology, Paris-Saclay University, Villejuif, France.
  12. Pediatric Oncology and Hematology, University Children's Hospital, Tuebingen, Germany.
  13. Assistance Publique Hôpitaux de Paris (APHP), Department of Endocrinology and Diabetes for Children, Bicêtre Paris-Sud, Le Kremlin Bicêtre, Paris, France.
  14. Paris-Saclay University, Paris-Sud University, Paris, France.
  15. SIREDO Oncology Center (Care, Innovation and Research for Children, Adolescents and Young Adults with Cancer), Institut Curie, PSL University, Paris, France.
  16. Pediatric Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy.
  17. Hematology-Oncology Division, Department of Women's and Children's Health, University Hospital, Padua, Italy.

PMID: 34174161 DOI: 10.1002/pbc.29025

Abstract

Adrenocortical tumours (ACTs) are rare during childhood. A complete surgical resection provides the best chance of cure, but the role and efficacy of the adjuvant therapy are still controversial. Various histologic criteria of malignancy for ACTs adopted in children do not facilitate comparative studies and are not completely shared. Therefore, a sharp demarcation between benign and malignant lesions has not been recognised, making it difficult to identify who potentially needs perioperative therapy. This manuscript presents the internationally harmonised recommendations for the diagnosis and treatment of ACTs in children and adolescents, established by the European Cooperative Study Group for Paediatric Rare Tumours (EXPeRT) group within the EU-funded project PARTNER (Paediatric Rare Tumours Network - European Registry).

© 2021 Wiley Periodicals LLC.

Keywords: EXPeRT; PARTNER; adolescents; adrenocortical tumours; children; diagnosis; guidelines; recommendations; therapy

References

  1. Dall'Igna P, Virgone C, De Salvo GL, et al. Adrenocortical tumours in Italian children: analysis of clinical characteristics and P53 status. Data from the national registries. J Pediatr Surg. 2014;49(9):1367-1371. - PubMed
  2. Wasserman JD, Novokmet A, Eichler-Jonsson C, et al. Prevalence and functional consequence of TP53 mutations in pediatric adrenocortical carcinoma: a children's oncology group study. J Clin Oncol. 2015;33(6):602-609. - PubMed
  3. Ribeiro RC, Sandrini Neto RS, Schell MJ, Lacerda L, Sambaio GA, Cat I. Adrenocortical carcinoma in children: a study of 40 cases. J Clin Oncol. 1990;8(1):67-74. - PubMed
  4. Rodriguez-Galindo C, Figueiredo BC, Zambetti GP, Ribeiro RC. Biology, clinical characteristics, and management of adrenocortical tumours in children. Pediatr Blood Cancer. 2005;45(3):265-273. - PubMed
  5. Custódio G, Komechen H, Figueiredo FRO, Fachin ND, Pianovski MAD, Figueiredo BC. Molecular epidemiology of adrenocortical tumours in southern Brazil. Mol Cell Endocrinol. 2012;351(1):44-51. - PubMed
  6. Wieneke JA, Thompson LDR, Heffess CS. Adrenal cortical neoplasms in the pediatric population: a clinicopathologic and immunophenotypic analysis of 83 patients. Am J Surg Pathol. 2003;27(7):867-881. - PubMed
  7. Jehangir S, Nanjundaiah P, Sigamani E, et al. Pathological prognostication of pediatric adrenocortical tumours: is a gold standard emerging? Pediatr Blood Cancer. 2019;66(4):e27567. - PubMed
  8. Ribeiro RC, Sandrini F, Figueiredo B, et al. An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma. Proc Natl Acad Sci U S A. 2001;98(16):9330-9335. - PubMed
  9. Latronico AC, Pinto EM, Domenice S, et al. An inherited mutation outside the highly conserved DNA-binding domain of the p53 tumor suppressor protein in children and adults with sporadic adrenocortical tumors. J Clin Endocrinol Metab. 2001;86(10):4970-4973. - PubMed
  10. Das S, Sengupta M, Islam N, et al. Weineke criteria, Ki-67 index and p53 status to study pediatric adrenocortical tumours: is there a correlation? J Pediatr Surg. 2016;51(11):1795-1800. - PubMed
  11. Chatterjee G, DasGupta S, Mukherjee G, et al. Usefulness of Wieneke criteria in assessing morphologic characteristics of adrenocortical tumours in children. Pediatr Surg Int. 2015;31(6):563-571. - PubMed
  12. Teinturier C, Pauchard MS, Brugières L, Landais P, Chaussain JL, Bougnères PF. Clinical and prognostic aspects of adrenocortical neoplasms in childhood. Med Pediatr Oncol. 1999;32(2):106-111. - PubMed
  13. Michalkiewicz E, Sandrini R, Figueiredo B, et al. Clinical and outcome characteristics of children with adrenocortical tumours: a report from the International Pediatric Adrenocortical Tumour Registry. J Clin Oncol. 2004;22(5):838-845. - PubMed
  14. Zambaiti E, Duci M, De Corti F, et al. Clinical prognostic factors in pediatric adrenocortical tumours: a meta-analysis. Pediatr Blood Cancer. 2021;68(3):e28836. - PubMed
  15. Picard C, Orbach D, Carton M, et al. Revisiting the role of the pathological grading in pediatric adrenal cortical tumours: results from a national cohort study with pathological review. Mod Pathol. 2019;32(4):546-559. - PubMed
  16. Picard C, Faure-Conter C, Leblond P, et al. Exploring heterogeneity of adrenal cortical tumours in children: the French pediatric rare tumour group (FRACTURE) experience. Pediatr Blood Cancer. 2020;67(2):e28086. - PubMed
  17. Cecchetto G, Ganarin A, Bien E, et al. Outcome and prognostic factors in high-risk childhood adrenocortical carcinomas: a report from the European Cooperative Study Group on Pediatric Rare Tumours (EXPeRT). Pediatr Blood Cancer. 2017;64(6):e26368. - PubMed
  18. Dykewicz CA, Centers for Disease Control and Prevention (U.S.), Infectious Diseases Society of America, American Society of Blood and Marrow Transplantation. Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Clin Infect Dis. 2001;33(2):139-144. - PubMed
  19. Orbach D, Ferrari A, Schneider D, et al. The European Pediatric Rare Tumors Network - European Registry (PARTNER) Project on very rare tumors in children. Pediatr Blood Cancer. 2021. In press. - PubMed
  20. Redlich A, Boxberger N, Strugala D, et al. Systemic treatment of adrenocortical carcinoma in children: data from the German GPOH-MET 97 trial. Klin Padiatr. 2012;224(6):366-371. - PubMed
  21. McAteer JP, Huaco JA, Gow KW. Predictors of survival in pediatric adrenocortical carcinoma: a Surveillance, Epidemiology, and End Results (SEER) program study. J Pediatr Surg. 2013;48(5):1025-1031. - PubMed
  22. Gulack BC, Rialon KL, Englum BR, et al. Factors associated with survival in pediatric adrenocortical carcinoma: an analysis of the National Cancer Data Base (NCDB). J Pediatr Surg. 2016;51(1):172-177. - PubMed
  23. Williams AR, Hammer GD, Else T. Transcutaneous biopsy of adrenocortical carcinoma is rarely helpful in diagnosis, potentially harmful, but does not affect patient outcome. Eur J Endocrinol. 2014;170(6):829-835. - PubMed
  24. Ribeiro RC, Pinto EM, Zambetti GP, Rodriguez-Galindo C. The International Pediatric Adrenocortical Tumour Registry initiative: contributions to clinical, biological, and treatment advances in pediatric adrenocortical tumours. Mol Cell Endocrinol. 2012;351(1):37-43. - PubMed
  25. Weiss LM, Medeiros LJ, Vickery AL. Pathologic features of prognostic significance in adrenocortical carcinoma. Am J Surg Pathol. 1989;13(3):202-206. - PubMed
  26. Dehner LP, Hill DA. Adrenal cortical neoplasms in children: why so many carcinomas and yet so many survivors? Pediatr Dev Pathol. 2009;12(4):284-291. - PubMed
  27. Dehner LP. Pediatric adrenocortical neoplasms: on the road to some clarity. Am J Surg Pathol. 2003;27(7):1005-1007. - PubMed
  28. Sandrini R, Ribeiro RC, DeLacerda L. Childhood adrenocortical tumours. J Clin Endocrinol Metab. 1997;82(7):2027-2031. - PubMed
  29. Rodriguez-Galindo C, Pappo AS, Krailo MD, et al. Treatment of childhood adrenocortical carcinoma (ACC) with surgery plus retroperitoneal lymph node dissection (RPLND) and multiagent chemotherapy: results of the Children's Oncology Group ARAR0332 protocol. J Clin Oncol. 2016;34:10515. - PubMed
  30. Fascetti-Leon F, Scotton G, Pio L, et al. Minimally invasive resection of adrenal masses in infants and children: results of a European multi-center survey. Surg Endosc. 2017;31(11):4505-4512. - PubMed
  31. Heloury Y, Muthucumaru M, Panabokke G, Cheng W, Kimber C, Leclair MD. Minimally invasive adrenalectomy in children. J Pediatr Surg. 2012;47(2):415-421. - PubMed
  32. Cundy TP, Marcus HJ, Clark J, et al. Robot-assisted minimally invasive surgery for pediatric solid tumours: a systematic review of feasibility and current status. Eur J Pediatr Surg. 2014;24(2):127-135. - PubMed
  33. Meignan P, Ballouhey Q, Lejeune J, et al. Robotic-assisted laparoscopic surgery for pediatric tumours: a bicenter experience. J Robot Surg. 2018;12(3):501-508. - PubMed
  34. St Peter SD, Valusek PA, Hill S, et al. Laparoscopic adrenalectomy in children: a multicenter experience. J Laparoendosc Adv Surg Tech A. 2011;21(7):647-649. - PubMed
  35. Hedican SP, Marshall FF. Adrenocortical carcinoma with intracaval extension. J Urol. 1997;158(6):2056-2061. - PubMed
  36. Hubertus J, Boxberger N, Redlich A, von Schweinitz D, Vorwerk P. Surgical aspects in the treatment of adrenocortical carcinomas in children: data of the GPOH-MET 97 trial. Klin Padiatr. 2012;224(3):143-147. - PubMed
  37. Fassnacht M, Terzolo M, Allolio B, et al. Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med. 2012;366(23):2189-2197. - PubMed
  38. Berruti A, Terzolo M, Sperone P, et al. Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial. Endocr Relat Cancer. 2005;12(3):657-666. - PubMed
  39. Fassnacht M, Dekkers O, Else T, et al. European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumours. Eur J Endocrinol. 2018;179(4):G1-G46. - PubMed
  40. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228-247. - PubMed
  41. Liang R, Weigand I, Lippert J, et al. Targeted gene expression profile reveals CDK4 as therapeutic target for selected patients with adrenocortical carcinoma. Front Endocrinol (Lausanne). 2020;11:219. - PubMed
  42. Lotfi Shahreza M, Ghadiri N, Green JR. A computational drug repositioning method applied to rare diseases: adrenocortical carcinoma. Sci Rep. 2020;10(1):8846. - PubMed
  43. Altieri B, Ronchi CL, Kroiss M, Fassnacht M. Next-generation therapies for adrenocortical carcinoma. Best Pract Res Clin Endocrinol Metab. 2020;34(3):101434. - PubMed
  44. Megerle F, Kroiss M, Hahner S, Fassnacht M. Advanced adrenocortical carcinoma - what to do when first-line therapy fails? Exp Clin Endocrinol Diabetes. 2019;127(2-3):109-116. - PubMed
  45. Luton JP, Cerdas S, Billaud L, et al. Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. N Engl J Med. 1990;322(17):1195-1201. - PubMed
  46. Haak HR, Hermans J, van de Velde CJ, et al. Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients. Br J Cancer. 1994;69(5):947-951. - PubMed
  47. Dickstein G, Shechner C, Arad E, Best LA, Nativ O. Is there a role for low doses of mitotane (o,p’-DDD) as adjuvant therapy in adrenocortical carcinoma? J Clin Endocrinol Metab. 1998;83(9):3100-3103. - PubMed
  48. Terzolo M, Angeli A, Fassnacht M, et al. Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med. 2007;356(23):2372-2380. - PubMed
  49. Zancanella P, Pianovski MAD, Oliveira BH, et al. Mitotane associated with cisplatin, etoposide, and doxorubicin in advanced childhood adrenocortical carcinoma: mitotane monitoring and tumour regression. J Pediatr Hematol Oncol. 2006;28(8):513-524. - PubMed
  50. Else T, Kim AC, Sabolch A, et al. Adrenocortical carcinoma. Endocr Rev. 2014;35(2):282-326. - PubMed
  51. Sabolch A, Else T, Griffith KA, et al. Adjuvant radiation therapy improves local control after surgical resection in patients with localized adrenocortical carcinoma. Int J Radiat Oncol Biol Phys. 2015;92(2):252-259. - PubMed
  52. Bornstein SR, Allolio B, Arlt W, et al. Diagnosis and treatment of primary adrenal insufficiency: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016;101(2):364-389. - PubMed
  53. Frebourg T, Bajalica Lagercrantz S, Oliveira C, Magenheim R, Evans DG, The European Reference Network GENTURIS. Guidelines for the Li-Fraumeni and heritable TP53-related cancer syndromes. Eur J Hum Genet. 2020;28(10):1379-1386. - PubMed
  54. Kratz CP, Achatz MI, Brugières L, et al. Cancer screening recommendations for individuals with Li-Fraumeni syndrome. Clin Cancer Res. 2017;23(11):e38-e45. - PubMed

Publication Types

Grant support